TransEngen

transengen.com

TransEngen® is a healthcare technology company focused on transforming patient access services by simplifying and accelerating the reimbursement process for Specialty Products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

INVITAE TO ACQUIRE CIITIZEN TO STRENGTHEN ITS PATIENT-CONSENTED HEALTH DATA PLATFORM TO IMPROVE PERSONAL OUTCOMES AND GLOBAL RESEARCH

Invitae | September 07, 2021

news image

Invitae , a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, whic...

Read More

RESEARCHERS IN THE US DEVELOP COMPUTER MODEL THAT PREDICTS HOW DRUGS AFFECT HEART RHYTHM

Edexlive | April 11, 2020

news image

Researchers have developed a computer model to screen drugs for unintended cardiac side effects, especially arrhythmia risk. Heart arrhythmia, also known as irregular heartbeat or cardiac dysrhythmia, is a group of conditions where the heartbeat is irregular, too slow, or too fast. "One main reason for a drug being removed from the market is potentially life-threatening arrhythmias. Even drugs developed to treat arrhythmia have ended up actually causing them," said study researcher Col...

Read More

HOW AI IS HELPING PHARMA COPE WITH SUPPLY CHAIN DISRUPTION

EPM Magazine | June 25, 2020

news image

As the Covid-19 crisis continues to unsettle global economies and business sectors worldwide, pharma companies are facing huge disruption to their supply chains and clinical research. And while research into potential Covid-19 vaccines and treatments is speeding along, the pandemic has slowed or brought to a halt clinical trials for other diseases, with organisations like Eli Lilly and other big name pharma’s’ putting the brakes on non Covid-19 trial activity. In fact,...

Read More

Business Insights

PHASEBIO PHARMACEUTICALS TO PARTICIPATE IN THE COWEN 42ND ANNUAL HEALTH CARE CONFERENCE

PhaseBio Pharmaceuticals, Inc. | February 25, 2022

news image

PhaseBio Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET. Interested parties can access the live and archived webcasts of the virtual...

Read More
news image

Pharma Tech

INVITAE TO ACQUIRE CIITIZEN TO STRENGTHEN ITS PATIENT-CONSENTED HEALTH DATA PLATFORM TO IMPROVE PERSONAL OUTCOMES AND GLOBAL RESEARCH

Invitae | September 07, 2021

Invitae , a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, whic...

Read More
news image

RESEARCHERS IN THE US DEVELOP COMPUTER MODEL THAT PREDICTS HOW DRUGS AFFECT HEART RHYTHM

Edexlive | April 11, 2020

Researchers have developed a computer model to screen drugs for unintended cardiac side effects, especially arrhythmia risk. Heart arrhythmia, also known as irregular heartbeat or cardiac dysrhythmia, is a group of conditions where the heartbeat is irregular, too slow, or too fast. "One main reason for a drug being removed from the market is potentially life-threatening arrhythmias. Even drugs developed to treat arrhythmia have ended up actually causing them," said study researcher Col...

Read More
news image

HOW AI IS HELPING PHARMA COPE WITH SUPPLY CHAIN DISRUPTION

EPM Magazine | June 25, 2020

As the Covid-19 crisis continues to unsettle global economies and business sectors worldwide, pharma companies are facing huge disruption to their supply chains and clinical research. And while research into potential Covid-19 vaccines and treatments is speeding along, the pandemic has slowed or brought to a halt clinical trials for other diseases, with organisations like Eli Lilly and other big name pharma’s’ putting the brakes on non Covid-19 trial activity. In fact,...

Read More
news image

Business Insights

PHASEBIO PHARMACEUTICALS TO PARTICIPATE IN THE COWEN 42ND ANNUAL HEALTH CARE CONFERENCE

PhaseBio Pharmaceuticals, Inc. | February 25, 2022

PhaseBio Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET. Interested parties can access the live and archived webcasts of the virtual...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us